
    
      The primary objective of this study is to assess the effects of administration of firibastat
      (QGC001) 500 mg oral (po) twice daily (bis in die [bid]) on blood pressure (BP) over 12 weeks
      in subjects with uncontrolled primary HTN.
    
  